ANI Pharmaceuticals
Manufactures oral solid dose products, as well as liquids and topicals.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $316m | Post IPO Convertible |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 4 % | 46 % | 54 % | 26 % | 37 % | 7 % | 8 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 7 % | 10 % | 22 % | 11 % | 26 % | 27 % | 29 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (20 %) | (15 %) | 4 % | (3 %) | 5 % | 5 % | 8 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 5 % | 7 % | 7 % | 7 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company focused on developing, manufacturing, and marketing high-quality branded and generic prescription pharmaceutical products. The company serves patients in need by providing FDA-approved medications that meet stringent safety and efficacy standards. ANI Pharmaceuticals operates in the pharmaceutical industry, targeting both healthcare providers and patients as its primary clients. The business model revolves around the development and commercialization of a broad portfolio of pharmaceutical products, including specialty drugs and generics. Revenue is generated through the sale of these products to pharmacies, hospitals, and healthcare providers. The company also engages in strategic acquisitions to expand its product offerings and market reach.
Keywords: biopharmaceutical, branded drugs, generic drugs, FDA-approved, healthcare, specialty pharmaceuticals, patient care, strategic acquisitions, pharmaceutical manufacturing, prescription medications.
Tech stack
Investments by ANI Pharmaceuticals
Edit
